Hims & Hers Health shares fell sharply after reporting a surprise first-quarter loss and revenue that missed expectations. The company, however, raised its full-year revenue outlook and signaled stronger second-quarter sales. The stock reaction underscores how investors are weighing results against ongoing regulatory scrutiny tied to weight-loss drugs and pricing momentum.
Weight-loss drugs have become a high-stakes global opportunity, and now a major Indian pharma player is stepping into the obesity fight with a fresh drug development. The move signals intensifying competition as companies chase demand for effective treatments, where speed to scale, manufacturing reach, and clinical promise could decide who leads the next wave of obesity medicines worldwide.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
